Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Acronyms EVINEC
- 10 Jun 2017 Biomarkers information updated
- 05 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 05 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.